Indian CRAMs Benefit From Global Slowdown With Increase Business
This article was originally published in PharmAsia News
Executive Summary
The contract research and manufacturing industry in India not only is weathering the global economic crisis, its business is increasing. Some foreign drug makers have stepped up their outsourcing to India to take advantage of reduced costs that can save some multinational companies as much as 40 percent. Analysts expect the CRAM business in India to reach the $3 billion mark a year from now, equal to a growth rate of 42 percent. The increase in CRAM business in India is the opposite of the experiences of other outsourcing businesses in the country. (Click here for more
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.